Nicola Bizzaro, Italy

Azienda Sanitaria Universitaria Integrata di Udine Laboratory of Clinical Pathology
Nicola Bizzaro, MD, was educated at the Medical School of the University of Padua (Italy). He completed his residence training in Clinical and Laboratory Hematology and subsequently in Clinical Pathology at the Padua University. After a 7-year experience in the Dept. of Internal Medicine and in the Immunohematology and Blood Transfusion Service, in 1986 Dr Bizzaro moved to the Dept. of Laboratory Medicine at the S.Donà di Piave Hospital (Venice), where he served as a Head of the Hematology, Coagulation, Immunology, and Allergology units. He undertook advanced training in Immunopathology as a visiting scientist at the Central Laboratory of the Netherland Blood Transfusion Service, Amsterdam, The Netherlands, from 1984 to 1998 (discontinually). Currently he is Head and Medical Director of the Laboratory of Clinical Pathology and Head of the Diagnostic Department at Gemona del Friuli and Tolmezzo Hospitals, Italy. Dr Bizzaro is the chairman of the Italian Society of Laboratory Working Group on Autoimmune Diseases, is a member of the Italian Association for Autoimmune Research and a founder-member of the Italian Interdisciplinary Forum for the Research in Autoimmune Diseases.

Presenter of 2 Presentations

SCREENING AND DISEASE-ORIENTED PROFILES IN THE DIAGNOSIS OF AUTOIMMUNE RHEUMATIC DISEASES.

Session Type
PARALLEL SESSIONS
Date
31.05.2021, Monday
Session Time
10:00 - 12:00
Room
HALL C
Lecture Time
10:00 - 10:15
Session Icon
Pre Recorded

ASSIGNING LIKELIHOOD RATIOS TO IMMUNOBLOT ASSAY RESULTS: A CLINICAL APPROACH IN AUTOIMMUNE REPORTING

Session Type
PARALLEL SESSIONS
Date
30.05.2021, Sunday
Session Time
10:00 - 12:00
Room
HALL F
Lecture Time
11:00 - 11:10
Session Icon
Pre Recorded

Abstract

Background and Aims

Recent studies showed how using likelihood ratios (LRs) to report autoantibodies results may improve their clinical interpretation. We aimed to assess whether LR calculation could be extended to antibodies to anti-extractable nuclear antigens (ENA) tests results, carried out by immunoblot (IB).

Methods

We evaluated result specific LRs for the ENA profile (Sm, RNP, Ro60, Ro52, Scl70, Jo1 and CENP-B) by an immunodot method (BlueDiver Quantrix, D-tek, Belgium) on 269 diagnostic samples from patients with ANA-associated autoimmune rheumatic diseases (AARD) [systemic lupus erythematosus (SLE) (n=79), primary Sjögren’s syndrome (SjS) (n=97), systemic sclerosis (SSc) (n=69), idiopathic inflammatory myositis (IIM) (n=12), mixed connective tissue disease (MCTD) (n=12)], and samples from 117 controls (81 diseased controls and 30 healthy blood donors).

Results

We calculated the LRs for each single anti-ENA antibody and for all antibodies grouped together, defining LR at different thresholds (Table). At 6 arbitrary units (AU) (corresponding to the cutoff indicated by the manufacturer), 12 AU, 25 AU, and 50 AU (corresponding to assay calibrators), overall positive LRs (all antibodies grouped together) for AARD were 14.5, 16.0, 41.2 and 65.0, respectively, while overall negative LRs for AARD were 0.45, 0.47, 0.54 and 0.62, respectively.

table-.png

Conclusions

Our study shows that expressing results in LR is also feasible using IB methods, even if some differences may be found due to local variation in the referred population. The use of LRs in addition to antibody values may facilitate the clinical interpretation of anti-ENA IB results and may contribute to harmonizing autoimmune laboratory reporting.

Hide